Antifibrotic therapy: is an antioxidative regimen the answer?

in human diabetic nephropathy. J Am Soc Nephrol 18: 1765–1776, 2007 14. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE: Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61: 2958–2966, 2012 15. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A: Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54: 1227–1241, 2011 16. Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L: Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 57: 2824–2833, 2008 17. LeeS, KimW,MoonSO,SungMJ, KimDH,KangKP, JangKY, LeeSY, Park BH,KohGY, Park SK: Renoprotective effect ofCOMP-angiopoietin-1 indb/ db mice with type 2 diabetes.Nephrol Dial Transplant 22: 396–408, 2007 18. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM: Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29: 2011–2022, 2009 19. Gavard J, Patel V, Gutkind JS: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14: 25–36, 2008 20. WinderlichM, Keller L, CagnaG, BroermannA, KamenyevaO, Kiefer F, Deutsch U, NottebaumAF, Vestweber D: VE-PTP controls blood vessel development by balancing Tie-2 activity. J Cell Biol 185: 657–671, 2009 21. YaoD, Taguchi T,Matsumura T, Pestell R, Edelstein D,Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, HammesHP, BrownleeM:High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282: 31038–31045, 2007